ArticleCureus2026
The Impact of an Engagement Solution Incorporating Antihypertensive Medications, Engagement Tools, and a Digital Application on Adherence Among Hypertensive Patients: A Real-World Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertension is the leading preventable risk factor for cardiovascular disease. The lack of treatment adherence is one of the most important challenges in managing and controlling hypertension. It is unclear whether patient-focused strategies and training for doctors are associated with better adherence and control.
objectiveThis study aimed to evaluate treatment adherence among hypertensive patients by comparing a group of patients who were part of a patient support program (PSP) and were using the engagement solution (ES), i.e., antihypertensive medications, engagement tools, and the Elfie application. These patients were included in group A by trained physicians. Group B features patients who were also part of the program but were using only medications.
methodsThis observational and retrospective study analyzed data from the PSP Sempre Cuidando (Laboratórios Servier do Brasil, Rio de Janeiro, BRA) and the Elfie app (Elfie, SGP), collected from across Brazil between November 2022 and October 2023. The population included hypertensive patients aged 18 years or older with arterial hypertension and possessing a medical prescription for antihypertensives referenced in the PSP. RESULTS AND
conclusionPatients were divided into two groups: 492 in group A and 984 in group B. The two groups were followed for six months. Group A demonstrated higher adherence to treatment, with an average treatment duration of 3.7 months compared to 2.7 months in group B, representing a 37% increase. Additionally, patients in group A showed statistically significant reductions in systolic blood pressure (SBP) and diastolic blood pressure (DBP) after six months versus their baseline.
conclusionsThe engagement solution was associated with higher levels of adherence and improved blood pressure control among hypertensive patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.